China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
NEW YORK, Nov. 21, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Middle District of North Carolina on behalf of investors who purchased Cempra, Inc. (NASDAQ:CEMP) securities between May 1, 2016 and November 1, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/cempra. There is no cost or obligation to you.
According to the complaint, during the Class Period, Cempra made false and/or misleading statements and/or failed to disclose that: (i) Cempra’s lead product candidate solithromycin posed significant safety risks for hepatotoxicity; and (ii) as a result of the foregoing, Cempra’s public statements were materially false and misleading at all relevant times.
On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review of solithromycin, highlighting a significant safety signal for hepatotoxicity. Upon this news, shares of Cempra fell over 60% during intraday trading.
If you suffered a loss in Cempra you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/cempra.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
